1. Home
  2. VTGN vs NYC Comparison

VTGN vs NYC Comparison

Compare VTGN & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.27

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Logo American Strategic Investment Co.

NYC

American Strategic Investment Co.

N/A

Current Price

$7.75

Market Cap

24.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
VTGN
NYC
Founded
1998
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
25.3M
24.5M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
VTGN
NYC
Price
$0.27
$7.75
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$0.90
N/A
AVG Volume (30 Days)
2.8M
60.6K
Earning Date
06-16-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
85.28
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$124.49
$56.73
Revenue Next Year
$353.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$7.00
52 Week High
$5.14
$13.97

Technical Indicators

Market Signals
Indicator
VTGN
NYC
Relative Strength Index (RSI) 43.49 36.90
Support Level $0.21 $7.10
Resistance Level $0.32 $8.69
Average True Range (ATR) 0.02 0.63
MACD 0.01 -0.17
Stochastic Oscillator 44.89 11.11

Price Performance

Historical Comparison
VTGN
NYC

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

Share on Social Networks: